Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “relacorilant”

8 pharma patents match "relacorilant" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 8
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 8 pharmaceutical patents matching "relacorilant" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

8 results for “relacorilant” · 30,257 patents in full index Clear search

  1. US 12097192

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  2. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  3. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Corcept Therapeutics Incorporated · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  4. US 11684612

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  5. US 11590113

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  6. US 11464764

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Corcept Therapeutics Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  7. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  8. US 11058670

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted